OR26. Investigating the impact of patient’s non-shared HLA-C Allotype expression levels in A 9/10 Single HLA-C mismatched hematopoieticstem cell transplantationsetting using two different HLA-C Expression proxy models
Sign Up to like & getrecommendations! Published in 2018 at "Human Immunology"
DOI: 10.1016/j.humimm.2018.07.031
Abstract: Aim Petersdorf et al. reported in 2014 an association between patient high expressed HLA-C (C) allotypes and inferior HSCT outcome using an imputed C-expression model (Apps et al., 2013). This study aims at: a) examining… read more here.
Keywords: non; hla mismatched; patient non; non shared ... See more keywords
Prior history of HLA-mismatched stem cell transplantation is a risk factor for graft failure in HLA-haploidentical transplantation
Sign Up to like & getrecommendations! Published in 2017 at "Bone Marrow Transplantation"
DOI: 10.1038/bmt.2016.278
Abstract: Prior history of HLA-mismatched stem cell transplantation is a risk factor for graft failure in HLA-haploidentical transplantation read more here.
Keywords: history hla; mismatched stem; hla mismatched; stem cell ... See more keywords
HLA-mismatched allogeneic adoptive immune therapy in severely immunosuppressed AIDS patients
Sign Up to like & getrecommendations! Published in 2021 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-021-00550-2
Abstract: Severely immunosuppressed AIDS patients with recurrent opportunistic infections (OIs) represent an unmet medical need even in the era of antiretroviral therapy (ART). Here we report the development of a human leukocyte antigen (HLA)-mismatched allogeneic adaptive… read more here.
Keywords: therapy; aids patients; mismatched allogeneic; hla mismatched ... See more keywords
Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation
Sign Up to like & getrecommendations! Published in 2019 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-019-0434-3
Abstract: The significance of low-dose total body irradiation (TBI) in HLA-mismatched reduced-intensity conditioning stem cell transplantation (RICT) remains unknown. We, retrospectively, evaluated the impact of low-dose TBI in patients with hematological malignancies who received first RICT… read more here.
Keywords: low dose; hla mismatched; transplantation; dose tbi ... See more keywords
No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease
Sign Up to like & getrecommendations! Published in 2021 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-020-01200-x
Abstract: Patients with advanced Ewing sarcoma (AES) carry a poor prognosis. Retrospectively, we analyzed 66 AES patients treated with allogeneic stem cell transplantation (allo-SCT) receiving HLA-mismatched (group A, n = 39) versus HLA-matched grafts (group B, n = 27). Median… read more here.
Keywords: group versus; allo sct; hla mismatched; group ... See more keywords
HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620720936935
Abstract: Background: Preconditioning intensity, donor choice and graft-versus-host disease (GVHD) prophylaxis of allogeneic hematopoietic cell transplantation (allo-HCT) for advanced myelofibrosis (MF) have not been fully elucidated. Methods: Thirty-five patients with advanced MF were treated with reduced-intensity… read more here.
Keywords: ferritin level; hla mismatched; mismatched donor; hct ... See more keywords
Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007596
Abstract: Abstract A common method to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation (HCT) from an HLA-mismatched unrelated donor (MMUD) is tacrolimus, methotrexate, and antithymocyte globulin (ATG). The use of posttransplant cyclophosphamide (PTCy) showed promise… read more here.
Keywords: mismatched unrelated; atg; unrelated donor; hla mismatched ... See more keywords
Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01229
Abstract: PURPOSE Immunopeptidome divergence between mismatched HLA-DP is a determinant of T-cell alloreactivity and clinical tolerability after fully HLA-A, -B, -C, -DRB1, -DQB1 matched unrelated donor hematopoietic cell transplantation (UD-HCT). Here, we tested this concept in… read more here.
Keywords: hla; pbm; unrelated donor; hla mismatched ... See more keywords
Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3+ T-Cells Infusion Causes An Augment of T-Cells With Mild CRS: A Multi-Centers Single-Arm Prospective Study on Elderly Acute Myeloid Leukemia and int-2/High Risk Myelodysplastic Syndrome Patients
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.741341
Abstract: Objective To evaluate the efficacy and safety of standard or low-dose chemotherapy followed by HLA-mismatched allogeneic T-cell infusion (allo-TLI) for the treatment of elderly patients with acute myeloid leukemia (AML) and patients with intermediate-2 to… read more here.
Keywords: chemotherapy; non ablative; high risk; hla mismatched ... See more keywords